Research and Markets: Novartis Partnering Guide 2008: An In-depth Insight into the...

Research and Markets: Novartis Partnering Guide 2008: An In-depth Insight into the Partnering Interests and Activities of one of the World's Leading Biopharma Companies

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/9cf987/novartis_partnerin)
has announced the addition of the "Novartis Partnering Guide 2008"
company profile to their offering.

This report provides all the information you require to better
understand Novartis and its partnering interests and activities over
the past five years.

One of the key aspects of partnering is finding those companies
that are potential partners for the development and commercialization
of the next generation of therapies as developed by innovative
biopharma R&D companies. A lot of resources are spent on finding
partners, identifying their interests and making contact to initiate
discussions.

Using this report, dealmakers will effectively and efficiently
determine the suitability of Novartis as a prospective partner, their
business development objectives, interests and recent partnering
activity, key partnering contacts, and partnering contract documents
signed with their recent partners.

The report provides a firm basis for initial due diligence into
Novartis as a prospective partner company.

The initial chapters of this report provide an orientation of
bigpharma's dealmaking and business activities.

Key benefits

- Detailed company profile of the company

- In-depth marketed and pipeline product activity for the company

- Partnering interests and therapy focus revealed

- Partnering activity since 2000 - number of deals per year

- Partnering activity for 2005-2008

- Activity by deal type

- Activity by phase of development

- Activity by therapeutic area

- List of recent partner companies

- Comprehensive access to actual contracts entered into by the
company and its partners*

- Insight into the terms included in a partnering agreement

- Understand the key deal terms the company has agreed in previous
deals

- Undertake due diligence to assess suitability of your proposed
deal terms for partner companies

*Subject to being published via regulatory requirements of the
Securities Exchange Commission.

Report scope

Novartis Partnering Guide 2008 is intended to provide the reader
with an in-depth understanding of the partnering activities and
interests of the company, enabling the effective assessment and
selection of partners of choice, based on the latest knowledge of a
company's approach to partnering.

Novartis Partnering Guide 2008 includes:

Detailed company profile including:

- Full contact details

- Business developer contact details including name, title, email
and telephone (where available)

- Marketed indications

- Pipeline indications

- Partnering interests and indications

- Partnering activity since 2000

- Current partner companies since 2005

- Partnering activity since 2005 by:

- Deal type

- Stage of development

- Therapy area

- Numerous charts showing the dealmaking activity of the company
since 2005

- The tools to enable effective and efficient preparation for
partnering negotiation with the company

- Listing of contract documents between the company and its
partners

- The leading M&A and partnering deals by value 2005-8

- Most active M&A and partnering dealmakers 2005-8

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Bigpharma - The Top 50

Chapter 3 - Most active bigpharma dealmakers

Chapter 4 - Top bigpharma deals - 2000-7

Chapter 5 - Submitting Opportunities to Bigpharma such as Novartis

Chapter 6 - Forthcoming bigpharma partnering events

Chapter 7 - Novartis - therapy locator

Chapter 8 - Bigpharma Company Profiles

For more information visit
http://www.researchandmarkets.com/research/9cf987/novartis_partnerin

Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Copyright Business Wire 2008